The initiation of coverage by a reputable analyst firm like HC Wainwright & Co. with a Buy rating and a significant price target suggests a strong positive outlook for Dyne Therapeutics. This endorsement is likely to influence investor sentiment positively in the short term, potentially leading to an increase in stock price.